Sapient’s High Complexity CLIA Laboratory Receives Accreditation From the College of American Pathologists
Complete the form below to unlock access to ALL audio articles.
Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, Sapient passed a rigorous evaluation process that involved an in-depth inspection of its clinical laboratory facilities, equipment, processes, quality control measures, and personnel qualifications.
“The results from the biomarker tests we develop and perform under CLIA can be used to direct patient care, be it for diagnosing disease, to identify responders vs. non-responders to a specific drug, or to evaluate drug safety and dosing strategies during clinical trials,” said Mo Jain, MD, PhD, Founder and CEO of Sapient. “Our clients rely on this data to guide their decision-making and ensure patient safety. It was very important for us to pursue CAP accreditation, to give customers the utmost confidence in our ability to develop robust clinical tests and provide accurate results that adhere to strict regulatory requirements.”
“As an organization, we are committed to upholding a culture of quality and to thoughtfully evolving our service offerings to meet the needs of our clients,” Dr. Jain continued. “With our CLIA-certified, CAP-accredited laboratory, we are able to support rapid translation of the biomarker discoveries we make for our biopharma customers to regulated clinical applications, and to further accelerate development and deployment of much-needed diagnostics and therapies.”